nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—bone cancer	0.551	1	CbGaD
Sulindac—PTGS2—Cisplatin—bone cancer	0.0465	0.529	CbGbCtD
Sulindac—SLC22A6—Methotrexate—bone cancer	0.0224	0.254	CbGbCtD
Sulindac—ALB—Methotrexate—bone cancer	0.019	0.217	CbGbCtD
Sulindac—MAPK3—periosteum—bone cancer	0.0101	0.254	CbGeAlD
Sulindac—PTGDR2—tendon—bone cancer	0.00315	0.0791	CbGeAlD
Sulindac—PTGS2—periosteum—bone cancer	0.00263	0.0661	CbGeAlD
Sulindac—AKR1B1—connective tissue—bone cancer	0.00244	0.0611	CbGeAlD
Sulindac—PTGS2—leg—bone cancer	0.0021	0.0527	CbGeAlD
Sulindac—PTGS2—hindlimb—bone cancer	0.00188	0.047	CbGeAlD
Sulindac—PTGS2—cartilage tissue—bone cancer	0.00185	0.0463	CbGeAlD
Sulindac—MAPK3—connective tissue—bone cancer	0.00177	0.0443	CbGeAlD
Sulindac—AKR1B1—tendon—bone cancer	0.00168	0.042	CbGeAlD
Sulindac—AKR1B1—bone marrow—bone cancer	0.00162	0.0407	CbGeAlD
Sulindac—AKR1B1—spinal cord—bone cancer	0.00162	0.0405	CbGeAlD
Sulindac—PTGS2—appendage—bone cancer	0.00161	0.0403	CbGeAlD
Sulindac—PPARD—tendon—bone cancer	0.00132	0.0331	CbGeAlD
Sulindac—MAPK3—tendon—bone cancer	0.00122	0.0305	CbGeAlD
Sulindac—MAPK3—bone marrow—bone cancer	0.00118	0.0295	CbGeAlD
Sulindac—MAPK3—spinal cord—bone cancer	0.00117	0.0294	CbGeAlD
Sulindac—PTGS1—connective tissue—bone cancer	0.00048	0.012	CbGeAlD
Sulindac—PTGS2—connective tissue—bone cancer	0.000459	0.0115	CbGeAlD
Sulindac—Hepatic failure—Doxorubicin—bone cancer	0.000434	0.00324	CcSEcCtD
Sulindac—Cardiac failure congestive—Doxorubicin—bone cancer	0.00043	0.00321	CcSEcCtD
Sulindac—Convulsion—Cisplatin—bone cancer	0.000428	0.0032	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000421	0.00315	CcSEcCtD
Sulindac—Myalgia—Cisplatin—bone cancer	0.00042	0.00314	CcSEcCtD
Sulindac—Discomfort—Cisplatin—bone cancer	0.000415	0.00311	CcSEcCtD
Sulindac—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000413	0.00309	CcSEcCtD
Sulindac—Renal impairment—Doxorubicin—bone cancer	0.000409	0.00306	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000405	0.00303	CcSEcCtD
Sulindac—Purpura—Doxorubicin—bone cancer	0.000404	0.00302	CcSEcCtD
Sulindac—Oedema—Cisplatin—bone cancer	0.000403	0.00301	CcSEcCtD
Sulindac—Anaphylactic shock—Cisplatin—bone cancer	0.000403	0.00301	CcSEcCtD
Sulindac—Thrombocytopenia—Cisplatin—bone cancer	0.000395	0.00295	CcSEcCtD
Sulindac—Tachycardia—Cisplatin—bone cancer	0.000393	0.00294	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.00039	0.00291	CcSEcCtD
Sulindac—Hyperhidrosis—Cisplatin—bone cancer	0.00039	0.00291	CcSEcCtD
Sulindac—Eosinophilia—Methotrexate—bone cancer	0.000385	0.00288	CcSEcCtD
Sulindac—Anorexia—Cisplatin—bone cancer	0.000384	0.00287	CcSEcCtD
Sulindac—Pancreatitis—Methotrexate—bone cancer	0.000381	0.00285	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000379	0.00283	CcSEcCtD
Sulindac—Hypotension—Cisplatin—bone cancer	0.000377	0.00282	CcSEcCtD
Sulindac—Gastritis—Epirubicin—bone cancer	0.000373	0.00279	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—bone cancer	0.000371	0.00278	CcSEcCtD
Sulindac—Pancytopenia—Methotrexate—bone cancer	0.000369	0.00276	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000367	0.00275	CcSEcCtD
Sulindac—Dysuria—Methotrexate—bone cancer	0.000364	0.00272	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—bone cancer	0.000364	0.00272	CcSEcCtD
Sulindac—Paraesthesia—Cisplatin—bone cancer	0.000362	0.00271	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—bone cancer	0.00036	0.00269	CcSEcCtD
Sulindac—Dyspnoea—Cisplatin—bone cancer	0.000359	0.00269	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—bone cancer	0.000357	0.00267	CcSEcCtD
Sulindac—Photosensitivity reaction—Methotrexate—bone cancer	0.000355	0.00265	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000351	0.00262	CcSEcCtD
Sulindac—Decreased appetite—Cisplatin—bone cancer	0.00035	0.00262	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—bone cancer	0.000349	0.00261	CcSEcCtD
Sulindac—Depression—Methotrexate—bone cancer	0.000346	0.00258	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—bone cancer	0.000346	0.00258	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—bone cancer	0.000345	0.00258	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000344	0.00257	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—bone cancer	0.000344	0.00257	CcSEcCtD
Sulindac—Renal failure—Methotrexate—bone cancer	0.000341	0.00255	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—bone cancer	0.00034	0.00254	CcSEcCtD
Sulindac—Dysuria—Epirubicin—bone cancer	0.00034	0.00254	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—bone cancer	0.000338	0.00253	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—bone cancer	0.000337	0.00252	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—bone cancer	0.000333	0.00249	CcSEcCtD
Sulindac—Sweating—Methotrexate—bone cancer	0.000332	0.00249	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—bone cancer	0.000332	0.00248	CcSEcCtD
Sulindac—Feeling abnormal—Cisplatin—bone cancer	0.000332	0.00248	CcSEcCtD
Sulindac—Haematuria—Methotrexate—bone cancer	0.000331	0.00247	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—bone cancer	0.00033	0.00247	CcSEcCtD
Sulindac—PTGS1—tendon—bone cancer	0.00033	0.00828	CbGeAlD
Sulindac—Hyperglycaemia—Epirubicin—bone cancer	0.000328	0.00245	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—bone cancer	0.000327	0.00245	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—bone cancer	0.000326	0.00244	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—bone cancer	0.000324	0.00242	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000322	0.00241	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—bone cancer	0.00032	0.00239	CcSEcCtD
Sulindac—Renal failure—Epirubicin—bone cancer	0.000319	0.00238	CcSEcCtD
Sulindac—Body temperature increased—Cisplatin—bone cancer	0.000319	0.00238	CcSEcCtD
Sulindac—PTGS1—spinal cord—bone cancer	0.000318	0.00799	CbGeAlD
Sulindac—Neuropathy peripheral—Epirubicin—bone cancer	0.000318	0.00238	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—bone cancer	0.000316	0.00236	CcSEcCtD
Sulindac—Jaundice—Epirubicin—bone cancer	0.000316	0.00236	CcSEcCtD
Sulindac—PTGS2—tendon—bone cancer	0.000316	0.00791	CbGeAlD
Sulindac—Conjunctivitis—Epirubicin—bone cancer	0.000315	0.00236	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—bone cancer	0.000315	0.00235	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—bone cancer	0.000315	0.00235	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—bone cancer	0.000311	0.00233	CcSEcCtD
Sulindac—Sweating—Epirubicin—bone cancer	0.000311	0.00233	CcSEcCtD
Sulindac—Haematuria—Epirubicin—bone cancer	0.000309	0.00231	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—bone cancer	0.000307	0.0023	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—bone cancer	0.000306	0.00229	CcSEcCtD
Sulindac—PTGS2—bone marrow—bone cancer	0.000306	0.00767	CbGeAlD
Sulindac—PTGS2—spinal cord—bone cancer	0.000304	0.00763	CbGeAlD
Sulindac—Hyperglycaemia—Doxorubicin—bone cancer	0.000304	0.00227	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—bone cancer	0.000303	0.00226	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—bone cancer	0.000302	0.00226	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—bone cancer	0.0003	0.00224	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000298	0.00223	CcSEcCtD
Sulindac—Hypersensitivity—Cisplatin—bone cancer	0.000297	0.00222	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—bone cancer	0.000295	0.00221	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—bone cancer	0.000294	0.0022	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—bone cancer	0.000294	0.0022	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—bone cancer	0.000293	0.00219	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—bone cancer	0.000293	0.00219	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—bone cancer	0.000292	0.00218	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—bone cancer	0.000291	0.00218	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—bone cancer	0.00029	0.00217	CcSEcCtD
Sulindac—Asthenia—Cisplatin—bone cancer	0.000289	0.00216	CcSEcCtD
Sulindac—Sweating—Doxorubicin—bone cancer	0.000288	0.00215	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—bone cancer	0.000286	0.00214	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—bone cancer	0.000283	0.00212	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—bone cancer	0.000281	0.0021	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—bone cancer	0.00028	0.00209	CcSEcCtD
Sulindac—Chills—Methotrexate—bone cancer	0.000279	0.00209	CcSEcCtD
Sulindac—Diarrhoea—Cisplatin—bone cancer	0.000276	0.00206	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—bone cancer	0.000275	0.00206	CcSEcCtD
Sulindac—Alopecia—Methotrexate—bone cancer	0.000275	0.00206	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—bone cancer	0.000272	0.00203	CcSEcCtD
Sulindac—Flushing—Epirubicin—bone cancer	0.00027	0.00202	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—bone cancer	0.00027	0.00202	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—bone cancer	0.000265	0.00198	CcSEcCtD
Sulindac—Chills—Epirubicin—bone cancer	0.000261	0.00195	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—bone cancer	0.00026	0.00195	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—bone cancer	0.00026	0.00194	CcSEcCtD
Sulindac—Alopecia—Epirubicin—bone cancer	0.000257	0.00192	CcSEcCtD
Sulindac—Vomiting—Cisplatin—bone cancer	0.000256	0.00192	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—bone cancer	0.000255	0.00191	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—bone cancer	0.000255	0.00191	CcSEcCtD
Sulindac—Rash—Cisplatin—bone cancer	0.000254	0.0019	CcSEcCtD
Sulindac—Dermatitis—Cisplatin—bone cancer	0.000254	0.0019	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—bone cancer	0.000251	0.00188	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—bone cancer	0.000251	0.00188	CcSEcCtD
Sulindac—Anaemia—Methotrexate—bone cancer	0.00025	0.00187	CcSEcCtD
Sulindac—Flushing—Doxorubicin—bone cancer	0.00025	0.00187	CcSEcCtD
Sulindac—Flatulence—Epirubicin—bone cancer	0.00025	0.00187	CcSEcCtD
Sulindac—Tension—Epirubicin—bone cancer	0.000249	0.00186	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—bone cancer	0.000248	0.00186	CcSEcCtD
Sulindac—Nervousness—Epirubicin—bone cancer	0.000246	0.00184	CcSEcCtD
Sulindac—Malaise—Methotrexate—bone cancer	0.000244	0.00183	CcSEcCtD
Sulindac—Vertigo—Methotrexate—bone cancer	0.000243	0.00182	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—bone cancer	0.000243	0.00181	CcSEcCtD
Sulindac—Chills—Doxorubicin—bone cancer	0.000242	0.00181	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—bone cancer	0.000241	0.0018	CcSEcCtD
Sulindac—Nausea—Cisplatin—bone cancer	0.000239	0.00179	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—bone cancer	0.000239	0.00179	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—bone cancer	0.000238	0.00178	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—bone cancer	0.000235	0.00176	CcSEcCtD
Sulindac—Convulsion—Methotrexate—bone cancer	0.000235	0.00176	CcSEcCtD
Sulindac—Anaemia—Epirubicin—bone cancer	0.000234	0.00175	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—bone cancer	0.000231	0.00173	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—bone cancer	0.000231	0.00172	CcSEcCtD
Sulindac—Chest pain—Methotrexate—bone cancer	0.000231	0.00172	CcSEcCtD
Sulindac—Myalgia—Methotrexate—bone cancer	0.000231	0.00172	CcSEcCtD
Sulindac—Tension—Doxorubicin—bone cancer	0.00023	0.00172	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—bone cancer	0.00023	0.00172	CcSEcCtD
Sulindac—Malaise—Epirubicin—bone cancer	0.000229	0.00171	CcSEcCtD
Sulindac—Discomfort—Methotrexate—bone cancer	0.000228	0.0017	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—bone cancer	0.000228	0.0017	CcSEcCtD
Sulindac—Vertigo—Epirubicin—bone cancer	0.000228	0.0017	CcSEcCtD
Sulindac—Syncope—Epirubicin—bone cancer	0.000227	0.0017	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—bone cancer	0.000227	0.0017	CcSEcCtD
Sulindac—Palpitations—Epirubicin—bone cancer	0.000224	0.00168	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—bone cancer	0.000223	0.00167	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—bone cancer	0.000221	0.00165	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—bone cancer	0.000221	0.00165	CcSEcCtD
Sulindac—Convulsion—Epirubicin—bone cancer	0.00022	0.00164	CcSEcCtD
Sulindac—Hypertension—Epirubicin—bone cancer	0.000219	0.00164	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—bone cancer	0.000218	0.00163	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—bone cancer	0.000217	0.00162	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—bone cancer	0.000217	0.00162	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—bone cancer	0.000216	0.00161	CcSEcCtD
Sulindac—Chest pain—Epirubicin—bone cancer	0.000216	0.00161	CcSEcCtD
Sulindac—Myalgia—Epirubicin—bone cancer	0.000216	0.00161	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—bone cancer	0.000214	0.0016	CcSEcCtD
Sulindac—Discomfort—Epirubicin—bone cancer	0.000213	0.00159	CcSEcCtD
Sulindac—Malaise—Doxorubicin—bone cancer	0.000212	0.00158	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—bone cancer	0.000211	0.00158	CcSEcCtD
Sulindac—Anorexia—Methotrexate—bone cancer	0.000211	0.00158	CcSEcCtD
Sulindac—Syncope—Doxorubicin—bone cancer	0.00021	0.00157	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—bone cancer	0.00021	0.00157	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—bone cancer	0.000207	0.00155	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—bone cancer	0.000207	0.00155	CcSEcCtD
Sulindac—Oedema—Epirubicin—bone cancer	0.000207	0.00155	CcSEcCtD
Sulindac—Hypotension—Methotrexate—bone cancer	0.000207	0.00154	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—bone cancer	0.000206	0.00154	CcSEcCtD
Sulindac—Shock—Epirubicin—bone cancer	0.000204	0.00152	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—bone cancer	0.000203	0.00152	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—bone cancer	0.000203	0.00151	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—bone cancer	0.000203	0.00151	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—bone cancer	0.000202	0.00151	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000202	0.00151	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—bone cancer	0.0002	0.0015	CcSEcCtD
Sulindac—Insomnia—Methotrexate—bone cancer	0.0002	0.0015	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—bone cancer	0.0002	0.00149	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—bone cancer	0.0002	0.00149	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—bone cancer	0.0002	0.00149	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—bone cancer	0.000199	0.00148	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—bone cancer	0.000197	0.00148	CcSEcCtD
Sulindac—Anorexia—Epirubicin—bone cancer	0.000197	0.00147	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—bone cancer	0.000197	0.00147	CcSEcCtD
Sulindac—Somnolence—Methotrexate—bone cancer	0.000197	0.00147	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—bone cancer	0.000195	0.00146	CcSEcCtD
Sulindac—Hypotension—Epirubicin—bone cancer	0.000193	0.00145	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—bone cancer	0.000192	0.00144	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—bone cancer	0.000192	0.00143	CcSEcCtD
Sulindac—Oedema—Doxorubicin—bone cancer	0.000192	0.00143	CcSEcCtD
Sulindac—Fatigue—Methotrexate—bone cancer	0.000191	0.00143	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000189	0.00141	CcSEcCtD
Sulindac—Shock—Doxorubicin—bone cancer	0.000188	0.00141	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—bone cancer	0.000188	0.0014	CcSEcCtD
Sulindac—Insomnia—Epirubicin—bone cancer	0.000187	0.0014	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—bone cancer	0.000187	0.0014	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—bone cancer	0.000186	0.00139	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—bone cancer	0.000185	0.00138	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—bone cancer	0.000185	0.00138	CcSEcCtD
Sulindac—Somnolence—Epirubicin—bone cancer	0.000184	0.00138	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—bone cancer	0.000183	0.00136	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—bone cancer	0.000182	0.00136	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—bone cancer	0.000182	0.00136	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—bone cancer	0.000181	0.00135	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—bone cancer	0.00018	0.00135	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—bone cancer	0.000179	0.00134	CcSEcCtD
Sulindac—Fatigue—Epirubicin—bone cancer	0.000178	0.00133	CcSEcCtD
Sulindac—Constipation—Epirubicin—bone cancer	0.000177	0.00132	CcSEcCtD
Sulindac—Urticaria—Methotrexate—bone cancer	0.000176	0.00131	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—bone cancer	0.000175	0.00131	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000174	0.0013	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—bone cancer	0.000173	0.00129	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—bone cancer	0.000172	0.00129	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—bone cancer	0.000171	0.00128	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—bone cancer	0.000171	0.00128	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—bone cancer	0.00017	0.00127	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—bone cancer	0.000169	0.00127	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—bone cancer	0.000169	0.00126	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—bone cancer	0.000166	0.00124	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—bone cancer	0.000165	0.00123	CcSEcCtD
Sulindac—Urticaria—Epirubicin—bone cancer	0.000164	0.00123	CcSEcCtD
Sulindac—Constipation—Doxorubicin—bone cancer	0.000164	0.00122	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—bone cancer	0.000164	0.00122	CcSEcCtD
Sulindac—Hypersensitivity—Methotrexate—bone cancer	0.000163	0.00122	CcSEcCtD
Sulindac—Asthenia—Methotrexate—bone cancer	0.000159	0.00119	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—bone cancer	0.000158	0.00118	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—bone cancer	0.000157	0.00117	CcSEcCtD
Sulindac—Pruritus—Methotrexate—bone cancer	0.000156	0.00117	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—bone cancer	0.000153	0.00114	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—bone cancer	0.000152	0.00114	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—bone cancer	0.000151	0.00113	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—bone cancer	0.000151	0.00113	CcSEcCtD
Sulindac—Asthenia—Epirubicin—bone cancer	0.000149	0.00111	CcSEcCtD
Sulindac—Pruritus—Epirubicin—bone cancer	0.000146	0.00109	CcSEcCtD
Sulindac—Dizziness—Methotrexate—bone cancer	0.000146	0.00109	CcSEcCtD
Sulindac—MAPK3—Cell Cycle, Mitotic—DHFR—bone cancer	0.000145	0.000778	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000144	0.000771	CbGpPWpGaD
Sulindac—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000144	0.000771	CbGpPWpGaD
Sulindac—MAPK3—PDGFR-beta signaling pathway—JUN—bone cancer	0.000143	0.000764	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—MDM2—bone cancer	0.000143	0.000763	CbGpPWpGaD
Sulindac—Diarrhoea—Epirubicin—bone cancer	0.000142	0.00106	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—ATF1—bone cancer	0.000141	0.000757	CbGpPWpGaD
Sulindac—Hypersensitivity—Doxorubicin—bone cancer	0.000141	0.00105	CcSEcCtD
Sulindac—MAPK3—Hemostasis—SPARC—bone cancer	0.000141	0.000753	CbGpPWpGaD
Sulindac—Vomiting—Methotrexate—bone cancer	0.000141	0.00105	CcSEcCtD
Sulindac—MAPK3—Signaling by ERBB4—MDM2—bone cancer	0.00014	0.000751	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—RB1—bone cancer	0.00014	0.00075	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.00014	0.000748	CbGpPWpGaD
Sulindac—Rash—Methotrexate—bone cancer	0.000139	0.00104	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—bone cancer	0.000139	0.00104	CcSEcCtD
Sulindac—MAPK3—L1CAM interactions—EGFR—bone cancer	0.000139	0.000741	CbGpPWpGaD
Sulindac—Headache—Methotrexate—bone cancer	0.000139	0.00104	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.000138	0.000738	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL3—bone cancer	0.000138	0.000738	CbGpPWpGaD
Sulindac—Asthenia—Doxorubicin—bone cancer	0.000137	0.00103	CcSEcCtD
Sulindac—Dizziness—Epirubicin—bone cancer	0.000137	0.00102	CcSEcCtD
Sulindac—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000136	0.000728	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—TP53—bone cancer	0.000136	0.000728	CbGpPWpGaD
Sulindac—Pruritus—Doxorubicin—bone cancer	0.000136	0.00101	CcSEcCtD
Sulindac—MAPK3—Downstream signal transduction—MDM2—bone cancer	0.000134	0.000717	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—MDM2—bone cancer	0.000134	0.000714	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—MDM2—bone cancer	0.000133	0.00071	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—RGS1—bone cancer	0.000132	0.000708	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GRM4—bone cancer	0.000132	0.000708	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—MDM2—bone cancer	0.000132	0.000707	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.000132	0.000706	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—TP53—bone cancer	0.000132	0.000706	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000132	0.000705	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000132	0.000705	CbGpPWpGaD
Sulindac—Vomiting—Epirubicin—bone cancer	0.000132	0.000984	CcSEcCtD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000131	0.000703	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000131	0.000703	CbGpPWpGaD
Sulindac—Nausea—Methotrexate—bone cancer	0.000131	0.000982	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	0.000131	0.000701	CbGpPWpGaD
Sulindac—Diarrhoea—Doxorubicin—bone cancer	0.000131	0.00098	CcSEcCtD
Sulindac—PPARD—Gene Expression—EZH2—bone cancer	0.000131	0.0007	CbGpPWpGaD
Sulindac—Rash—Epirubicin—bone cancer	0.000131	0.000976	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—bone cancer	0.00013	0.000975	CcSEcCtD
Sulindac—MAPK3—Cell Cycle—DHFR—bone cancer	0.00013	0.000696	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—JUN—bone cancer	0.00013	0.000693	CbGpPWpGaD
Sulindac—Headache—Epirubicin—bone cancer	0.00013	0.000969	CcSEcCtD
Sulindac—MAPK3—ErbB1 downstream signaling—EGFR—bone cancer	0.000129	0.00069	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—GNA11—bone cancer	0.000129	0.000689	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—JUN—bone cancer	0.000128	0.000682	CbGpPWpGaD
Sulindac—Dizziness—Doxorubicin—bone cancer	0.000127	0.000947	CcSEcCtD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000127	0.000677	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—MMP9—bone cancer	0.000126	0.000675	CbGpPWpGaD
Sulindac—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000125	0.000668	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—MDM2—bone cancer	0.000124	0.000665	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—MDM2—bone cancer	0.000124	0.000665	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.000124	0.000665	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NDUFA12—bone cancer	0.000124	0.000665	CbGpPWpGaD
Sulindac—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000123	0.000659	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—MDM2—bone cancer	0.000123	0.000659	CbGpPWpGaD
Sulindac—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000123	0.000658	CbGpPWpGaD
Sulindac—Nausea—Epirubicin—bone cancer	0.000123	0.000919	CcSEcCtD
Sulindac—MAPK3—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000122	0.000653	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—CDK4—bone cancer	0.000122	0.000652	CbGpPWpGaD
Sulindac—Vomiting—Doxorubicin—bone cancer	0.000122	0.00091	CcSEcCtD
Sulindac—MAPK3—Signaling by PDGF—MDM2—bone cancer	0.000122	0.00065	CbGpPWpGaD
Sulindac—MAPK3—Apoptosis Modulation and Signaling—TP53—bone cancer	0.000122	0.00065	CbGpPWpGaD
Sulindac—Rash—Doxorubicin—bone cancer	0.000121	0.000903	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—bone cancer	0.000121	0.000902	CcSEcCtD
Sulindac—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00012	0.000643	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—RB1—bone cancer	0.00012	0.000642	CbGpPWpGaD
Sulindac—Headache—Doxorubicin—bone cancer	0.00012	0.000897	CcSEcCtD
Sulindac—MAPK3—Cellular Senescence—MDM2—bone cancer	0.00012	0.000639	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000119	0.000634	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TGFBR2—bone cancer	0.000118	0.000631	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ENO2—bone cancer	0.000118	0.000631	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—EGFR—bone cancer	0.000118	0.000629	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—JUN—bone cancer	0.000117	0.000627	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000117	0.000626	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL3—bone cancer	0.000117	0.000625	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GRM1—bone cancer	0.000115	0.000613	CbGpPWpGaD
Sulindac—Nausea—Doxorubicin—bone cancer	0.000114	0.00085	CcSEcCtD
Sulindac—AKR1B1—Metabolism—PTGS2—bone cancer	0.000113	0.000607	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000113	0.000603	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—JUN—bone cancer	0.000113	0.000603	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IGF1R—bone cancer	0.000111	0.000594	CbGpPWpGaD
Sulindac—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000111	0.000593	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.00011	0.000589	CbGpPWpGaD
Sulindac—PPARD—Metabolism—DHFR—bone cancer	0.000109	0.000585	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000109	0.000583	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CHEK2—bone cancer	0.000109	0.000581	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	0.000108	0.000578	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ATF1—bone cancer	0.000108	0.000577	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KIT—bone cancer	0.000108	0.000575	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000107	0.000572	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—RB1—bone cancer	0.000106	0.000567	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—NR1I2—bone cancer	0.000104	0.000557	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—JUN—bone cancer	0.000104	0.000556	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MET—bone cancer	0.000103	0.000553	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NT5C3A—bone cancer	0.000103	0.000551	CbGpPWpGaD
Sulindac—PPARD—Metabolism—GNA11—bone cancer	0.000102	0.000547	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000102	0.000546	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—EGFR—bone cancer	0.000102	0.000545	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000102	0.000544	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—BRAF—bone cancer	0.000101	0.000541	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.000101	0.00054	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TP53—bone cancer	9.87e-05	0.000528	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NDUFA12—bone cancer	9.87e-05	0.000528	CbGpPWpGaD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—TP53—bone cancer	9.8e-05	0.000524	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—EGFR—bone cancer	9.76e-05	0.000522	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	9.76e-05	0.000522	CbGpPWpGaD
Sulindac—MAPK3—M Phase—RB1—bone cancer	9.69e-05	0.000518	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—EGFR—bone cancer	9.6e-05	0.000513	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	9.39e-05	0.000502	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—CYP3A4—bone cancer	9.32e-05	0.000498	CbGpPWpGaD
Sulindac—PPARD—Metabolism—CYP3A4—bone cancer	9.27e-05	0.000496	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.23e-05	0.000493	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—BRCA2—bone cancer	9.21e-05	0.000493	CbGpPWpGaD
Sulindac—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	9.19e-05	0.000491	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—EGFR—bone cancer	9.17e-05	0.00049	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—EGFR—bone cancer	9.12e-05	0.000488	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—EGFR—bone cancer	9.08e-05	0.000485	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—EGFR—bone cancer	9.03e-05	0.000483	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—MDM2—bone cancer	9.03e-05	0.000483	CbGpPWpGaD
Sulindac—MAPK3—Mitotic M-M/G1 phases—RB1—bone cancer	8.88e-05	0.000475	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—EGFR—bone cancer	8.86e-05	0.000474	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.82e-05	0.000471	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NDUFA12—bone cancer	8.76e-05	0.000468	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MMP9—bone cancer	8.65e-05	0.000463	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP2—bone cancer	8.63e-05	0.000461	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—EGFR—bone cancer	8.5e-05	0.000455	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—EGFR—bone cancer	8.5e-05	0.000455	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	8.5e-05	0.000455	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—MDM2—bone cancer	8.47e-05	0.000453	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—EGFR—bone cancer	8.42e-05	0.00045	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.41e-05	0.00045	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.41e-05	0.00045	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—EGFR—bone cancer	8.35e-05	0.000446	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—EGFR—bone cancer	8.31e-05	0.000444	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NT5C3A—bone cancer	8.18e-05	0.000437	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—SMO—bone cancer	8.08e-05	0.000432	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KIT—bone cancer	8.05e-05	0.000431	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8e-05	0.000428	CbGpPWpGaD
Sulindac—ALB—Metabolism—NDUFA12—bone cancer	7.99e-05	0.000427	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—GSTP1—bone cancer	7.97e-05	0.000426	CbGpPWpGaD
Sulindac—PPARD—Metabolism—GSTP1—bone cancer	7.93e-05	0.000424	CbGpPWpGaD
Sulindac—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	7.86e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—JUN—bone cancer	7.85e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GRM4—bone cancer	7.82e-05	0.000418	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RGS1—bone cancer	7.82e-05	0.000418	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—EIF2S1—bone cancer	7.7e-05	0.000412	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PLAU—bone cancer	7.66e-05	0.00041	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDK4—bone cancer	7.64e-05	0.000409	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—BRAF—bone cancer	7.57e-05	0.000405	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—bone cancer	7.56e-05	0.000404	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	7.53e-05	0.000403	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—bone cancer	7.44e-05	0.000398	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GNA11—bone cancer	7.39e-05	0.000395	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CDK4—bone cancer	7.38e-05	0.000395	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MET—bone cancer	7.38e-05	0.000395	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—EGFR—bone cancer	7.34e-05	0.000392	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.28e-05	0.000389	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NT5C3A—bone cancer	7.26e-05	0.000388	CbGpPWpGaD
Sulindac—MAPK3—Disease—ENO2—bone cancer	7.19e-05	0.000385	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—EGFR—bone cancer	6.99e-05	0.000374	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.96e-05	0.000372	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—bone cancer	6.86e-05	0.000367	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDK4—bone cancer	6.83e-05	0.000365	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GRM1—bone cancer	6.78e-05	0.000362	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SPARC—bone cancer	6.78e-05	0.000362	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.71e-05	0.000359	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL3—bone cancer	6.7e-05	0.000358	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—EZH2—bone cancer	6.69e-05	0.000358	CbGpPWpGaD
Sulindac—MAPK3—Disease—DHFR—bone cancer	6.67e-05	0.000357	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—RB1—bone cancer	6.64e-05	0.000355	CbGpPWpGaD
Sulindac—ALB—Metabolism—NT5C3A—bone cancer	6.62e-05	0.000354	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP9—bone cancer	6.48e-05	0.000347	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MDM2—bone cancer	6.34e-05	0.000339	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ATF1—bone cancer	6.28e-05	0.000336	CbGpPWpGaD
Sulindac—ALB—Hemostasis—GNA11—bone cancer	6.2e-05	0.000331	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP2—bone cancer	6.16e-05	0.000329	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KIT—bone cancer	6.14e-05	0.000328	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL3—bone cancer	6.12e-05	0.000327	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.05e-05	0.000323	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—RB1—bone cancer	5.94e-05	0.000318	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—bone cancer	5.87e-05	0.000314	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—EGFR—bone cancer	5.79e-05	0.00031	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL3—bone cancer	5.62e-05	0.0003	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NDUFA12—bone cancer	5.59e-05	0.000299	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—JUN—bone cancer	5.51e-05	0.000295	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MMP9—bone cancer	5.36e-05	0.000287	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—EGFR—bone cancer	5.24e-05	0.00028	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—bone cancer	5.18e-05	0.000277	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MDM2—bone cancer	5.07e-05	0.000271	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFBR2—bone cancer	4.84e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MDM2—bone cancer	4.83e-05	0.000258	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SMO—bone cancer	4.78e-05	0.000255	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.76e-05	0.000254	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NT5C3A—bone cancer	4.63e-05	0.000247	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP9—bone cancer	4.63e-05	0.000247	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ENO2—bone cancer	4.51e-05	0.000241	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GNA11—bone cancer	4.37e-05	0.000234	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EGFR—bone cancer	4.33e-05	0.000232	CbGpPWpGaD
Sulindac—PTGS2—Disease—ENO2—bone cancer	4.28e-05	0.000229	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—JUN—bone cancer	4.2e-05	0.000225	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—DHFR—bone cancer	4.19e-05	0.000224	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—bone cancer	4.11e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ATF1—bone cancer	4.06e-05	0.000217	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.99e-05	0.000214	CbGpPWpGaD
Sulindac—PTGS2—Disease—DHFR—bone cancer	3.97e-05	0.000212	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL3—bone cancer	3.96e-05	0.000212	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GNA11—bone cancer	3.91e-05	0.000209	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EGFR—bone cancer	3.74e-05	0.0002	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PLAU—bone cancer	3.69e-05	0.000197	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—bone cancer	3.64e-05	0.000195	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ENO2—bone cancer	3.58e-05	0.000192	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KIT—bone cancer	3.57e-05	0.000191	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP3A4—bone cancer	3.55e-05	0.00019	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.53e-05	0.000189	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFBR2—bone cancer	3.39e-05	0.000181	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—DHFR—bone cancer	3.32e-05	0.000178	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EGFR—bone cancer	3.3e-05	0.000177	CbGpPWpGaD
Sulindac—MAPK3—Disease—KIT—bone cancer	3.3e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1R—bone cancer	3.19e-05	0.00017	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ENO2—bone cancer	3.18e-05	0.00017	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GNA11—bone cancer	3.11e-05	0.000166	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—bone cancer	3.1e-05	0.000166	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—bone cancer	3.08e-05	0.000165	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTP1—bone cancer	3.03e-05	0.000162	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—DHFR—bone cancer	2.95e-05	0.000158	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—bone cancer	2.91e-05	0.000155	CbGpPWpGaD
Sulindac—ALB—Metabolism—ENO2—bone cancer	2.9e-05	0.000155	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFBR2—bone cancer	2.88e-05	0.000154	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP3A4—bone cancer	2.82e-05	0.000151	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MDM2—bone cancer	2.81e-05	0.000151	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GNA11—bone cancer	2.76e-05	0.000147	CbGpPWpGaD
Sulindac—ALB—Metabolism—DHFR—bone cancer	2.69e-05	0.000144	CbGpPWpGaD
Sulindac—MAPK3—Disease—MDM2—bone cancer	2.6e-05	0.000139	CbGpPWpGaD
Sulindac—ALB—Metabolism—GNA11—bone cancer	2.51e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—bone cancer	2.51e-05	0.000134	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP3A4—bone cancer	2.5e-05	0.000134	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.49e-05	0.000133	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—bone cancer	2.45e-05	0.000131	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTP1—bone cancer	2.41e-05	0.000129	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIT—bone cancer	2.31e-05	0.000124	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP3A4—bone cancer	2.28e-05	0.000122	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.27e-05	0.000121	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—bone cancer	2.17e-05	0.000116	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—bone cancer	2.14e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—bone cancer	2.11e-05	0.000113	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO2—bone cancer	2.03e-05	0.000108	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—bone cancer	1.96e-05	0.000105	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—bone cancer	1.95e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—bone cancer	1.92e-05	0.000103	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—DHFR—bone cancer	1.88e-05	0.000101	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—bone cancer	1.84e-05	9.86e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—bone cancer	1.82e-05	9.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—bone cancer	1.78e-05	9.5e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GNA11—bone cancer	1.76e-05	9.4e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP3A4—bone cancer	1.59e-05	8.52e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.59e-05	8.48e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—bone cancer	1.58e-05	8.46e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—bone cancer	1.57e-05	8.4e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—bone cancer	1.55e-05	8.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—bone cancer	1.54e-05	8.23e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—bone cancer	1.48e-05	7.92e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—bone cancer	1.36e-05	7.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—bone cancer	1.24e-05	6.65e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—bone cancer	1.11e-05	5.92e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—bone cancer	1.06e-05	5.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—bone cancer	1.04e-05	5.58e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—bone cancer	1.01e-05	5.4e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—bone cancer	7.06e-06	3.78e-05	CbGpPWpGaD
